Format

Send to

Choose Destination
See comment in PubMed Commons below
Vet J. 2004 Mar;167(2):158-66.

Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.

Author information

  • 1Hematology-Cytology-Immunology Laboratory, Departement des Animaux de Compagnie, Ecole Nationale Vétérinaire de Lyon, 1 Avenue Bourgelat, B.P. 83, Marcy L'Etoile 69280, France. f.ponce@vet-lyon.fr

Abstract

The aim of this study was to determine the response of different morphological subtypes of canine lymphoma to a standardized therapeutic protocol. Diagnosis of lymphoma was based on cytohistological analysis and immunophenotyping with antibodies against CD3 and CD79a of an enlarged lymph node or an extranodal mass. Fifty-seven cases were classified according to the updated Kiel classification adapted to the canine species, into 24 B-cell lymphomas (20 centroblastic polymorphic and four Burkitt-type subtypes), and 33 T-cell lymphomas (10 pleomorphic mixed, 10 lymphoblastic, eight unclassifiable high grade plasmacytoid, and five small clear-cell subtypes). All dogs were clinically staged at diagnosis. The protocol used l-asparaginase, vincristine, cyclophosphamide, doxorubicin, and prednisone. First remission duration and overall survival time were evaluated. Although the T-cell phenotype was associated, on the whole, with a poor prognosis, as previously reported in veterinary and human medicine, the study showed significant prognostic differences between the B- and the T-cell subtypes of canine lymphoma and suggests that clinico-morphological characterization of the disease is justified in dogs, as in humans.

PMID:
14975390
DOI:
10.1016/j.tvjl.2003.10.009
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center